PRADAXA BLEEDING LAWSUITS UPDATE JULY 2012 -
LEGAL CASES CONSOLIDATED IN MULTI DISTRICT LITIGATION
As anticipated, mounting lawsuits against the manufacturer of PRADAXA (DABIGATRAN ETEXILATE), BOEHRINGER INGELHEIM, have been consolidated into a coordinated Multi-District Litigation (MDL). This will facilitate National litigation being filed in at one centralized location within the Federal court system. It is possible that similar State coordinated proceedings will be organized as PRADAXA BLEEDING cases continue to be screened and filed.
As noted below, PRADAXA (DABIGATRAN ETEXILATE) is a fairly new anti-coagulant that was celebrated as an alternative to treatment with COUMADIN or WARFARIN. In other words, it was marketed and packaged to providers/prescribers, as a new and improved way to treat patients in need of anti-coagulant therapy. However, unlike COUMADIN or WARFARIN, which have over 50 years of studies and practical use associated with the product, PRADAXA (DABIGATRAN ETEXILATE) has only been approved for use in the United States since October 2010. In this short period of time, the effects of PRADAXA BLOOD and adverse bleeding events have raised International concerns. In the United States, the ISMP has noted that the blood thinner has been linked to a number of deaths and become the most widely reported drug in association with adverse event reports to the U.S. Food & Drug Administration.
The number of pending lawsuits against BOEHRINGER INGELHEIM is expected to grow through 2012. Sadly, adverse events involved in potential lawsuits include deaths, strokes, heart attacks, as well as deblitating or disabling injuries from the effects of PRADAXA BLOOD.
FREE CASE EVALUATIONS ARE AVAILABLE FROM THE SPONSOR OF THIS SITE THROUGH USE OF THE CONTACT FORM BELOW.